Akademik Veri Yönetim Sistemi
Journal of Back and Musculoskeletal Rehabilitation, cilt.18, sa.3-4, ss.85-89, 2005 (SCI-Expanded)
The objective of the study was to compare the effects of alendronate, risedronate and calcitonin on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. The patients (n=200) were equally divided to one of four treatment groups: alendronate 10 mg/daily, risedronate 5 mg/daily, calcitonin 200 IU/daily and control group for 12 months. All groups also received 1000 mg of calcium/daily. The control group received only 1000 mg calcium/daily. Serum osteocalcin (OC), bone specific alkaline phosphatase (BSAP) and urinary deoxypyridinoline (uDPD) levels were determined. There are increases in BMD at two regions, at the end of 12 months in four groups. The mean increases in BMD at 12 months, at the lumbar spine and hip respectively, were: alendronate (p < 0.05, p < 0.001), risedronate (p < 0.001, p < 0.01), calcitonin (p < 0.05, p < 0.01) and control group (p < 0.05 for both site). In comparison with control group, the mean changes in BMD at the spine and hip were greater in the other groups (p < 0.05 for both region). uDPD levels were gradually reduced at the end of study in all groups (p < 0.01 for three groups), while no significant change was found in calcium group. The treatment with alendronate produced significantly greater increases in total hip BMD than did risedronate and calcitonin and tretment with risedronate produced significantly greater increases in lumbar spine BMD than did alendronate and calcitonin over 12 months. This study demonstrated the efficacy of alendronate, risedronate and calcitonin in preventing the bone loss related to postmenopausal osteoporosis. © 2005 IOS Press and the authors. All rights reserved. Indications:50 patients with postmenopausal osteoporosis. Patients:200 postmenopausal female patients, of which only 188 patients were included in the final analysis, aged 49 to 64 years (mean, 56.2 years) were studied. Miacalcic group: 50 patients, of which only 48 patients completed the study. Alendronate group: 50 patients, of which only 47 patients completed the study. Risedronate group: 50 patients, of which only 47 patients completed the study. Control (elemental calcium only) group: 50 patients, of which only 46 patients completed the study. TypeofStudy:A study investigating the effects of Miacalcic, alendronate, and risedronate treatment on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal patients with osteoporosis. A comparative, controlled, open study. DosageDuration:200 IU daily intranasally. Duration: 12 months. ComparativeDrug:Alendronate sodium (Fosamax): 10 mg daily orally. Duration: 12 months. Risedronate (Actonel): 5 mg daily orally. Duration: 12 months. Results:Following Miacalcic, alendronate, risedronate, and calcium treatment, no significant changes on serum BSAP and OC levels were noted. The uDPD levels were gradually reduced in Miacalcic, alendronate, and risedronate groups (p<0.01 for each groups), while no significant change in the control group. Total lumbar spine and hip BMD increased significantly in the alendronate-treated patients during the treatment period (p< 0.05, p< 0.01, respectively). A significant increase in both regions was also noted in the risedronate group (p<0.001, p<0.01, respectively). Similarly in the Miacalcic-treated patients, a significant increase in both sites was observed at the end of treatment period (p< 0.05, p< 0.01, respectively). Significantly greater increases in total hip and lumbar spine BMD were observed with alendronate-treated patients. Reduction in serum BSAP and OC levels were not significant in Miacalcic, alendronate, and risedronate groups compared with that of the control group (p>0.05). Miacalcic, alendronate, and risedronate groups showed significant decreases in uDPD levels compared with the control group (p< 0.05 for alendronate and risedronate groups, p< 0.01 for Miacalcic group). There were significant increases in the lumbar spine and total hip BMD (p< 0.05, p<0.05 for all groups) in the Miacalcic, alendronate, risedronate groups compared with control group at the end of first year. AdverseEffects:No adverse effects which can cause the stopping of the medications in all groups were observed. AuthorsConclusions:This study clearly demonstrated the efficacy of alendronate, risedronate and calcitonin in preventing the bone loss related to postmenopausal osteoporosis. FreeText:BMD (energy x-ray absorptiometry; DEXA) was measured at the lumbar spine (L1-L4 total value) and at the hip. BMD and markers of bone formation and degradation were measured at baseline and after 12 months. Concomitant drug was elemental calcium 1000 mg orally (calcium lactate, gluconate, or carbonate). Other tests: serum osteocalcin (OC) and bone-specific alkaline phosphatase (BSAP) levels, urinary deoxypyridinoline (uDPD), and body mass index.